Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 327Neoplasm Metastasis 40Neoplasms 25Advanced Breast Cancer 19Ovarian Neoplasms 18Carcinoma, Non-Small-Cell Lung 14Endometrial Neoplasms 11Prostatic Neoplasms 10Hereditary Sensory and Autonomic Neuropathies 10Triple Negative Breast Neoplasms 8Colorectal Neoplasms 6Breast Cancer Metastatic 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Multiple Endocrine Neoplasia Type 1 5Carcinoma, Ovarian Epithelial 5Breast Diseases 5Neoplasms by Site 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Lobular 3Breast Neoplasm Female 3Uterine Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Fulvestrant 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Uterine Corpus Carcinoma × Fulvestrant × Clear all
NCT00006903 2019-03-20

Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

GOG Foundation

Phase 2 Unknown
67 enrolled 9 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡